Seattle Genetics (SGEN), Takeda Announces Publication of Final ADCETRIS Phase 2 Data in r/r Hodgkin Lymphoma
Tweet Send to a Friend
Seattle Genetics, Inc. (NASDAQ: SGEN) and Takeda Pharmaceutical Company Limited announced the final data of the ADCETRIS (brentuximab vedotin) monotherapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE